TeraFold Biologics

TeraFold Biologics

TeraFold Biologics is developing an integrated computational platform for discovery, modeling, and pre-clinical validation of alternative.

  • Edit
DateInvestorsAmountRound

$40.0k

Seed
Total Funding000k
Notes (0)
More about TeraFold Biologics
Made with AI
Edit

TeraFold Biologics, founded in 2012 by Pavel Paramonov, Lilian Parra-Gessert, and Ivo Georgiev, is a biotechnology firm headquartered in San Francisco. The company is focused on the development of an integrated computational platform designed for the discovery and preclinical validation of alternative protein scaffolds. This platform underpins an end-to-end service for protein library design, engineering, and production.

The company's core business revolves around its computational platform, which facilitates the discovery, modeling, and preclinical validation of protein scaffolds for therapeutic and diagnostic use. By offering a comprehensive service that covers the entire process from design to production, TeraFold Biologics aims to support biotechnology and pharmaceutical companies in their drug development efforts. The business operates on a B2B model, providing its specialized services to other entities within the health and biotech sectors. The platform's primary application areas include oncology and neurology, indicating a focus on diseases with complex biological pathways.

TeraFold Biologics' platform addresses a critical need in the pharmaceutical industry for more efficient and effective drug discovery methods. Traditional 'one drug-one protein' approaches often fall short in treating complex diseases like cancer, which can involve multiple dysregulated proteins. The company's technology is designed to create therapeutics capable of targeting several disease-causing proteins simultaneously. This approach has the potential to accelerate the development of new treatments and improve patient outcomes in challenging therapeutic areas. The market for biologics contract development and manufacturing is experiencing significant growth, driven by the increasing complexity of new treatment modalities and the need for specialized expertise and infrastructure. Keywords: protein scaffold discovery, computational protein design, preclinical validation, therapeutic protein engineering, diagnostic protein scaffolds, B2B biotechnology services, oncology drug discovery, neurology therapeutics, alternative protein scaffolds, protein library design, biologics computational platform, end-to-end protein services, biopharmaceutical support, drug discovery platform, therapeutic modeling, preclinical services, custom protein production, complex disease therapeutics, multi-target therapeutics, biotech computational services

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads